Literature DB >> 22441533

A high value of serum des-γ-carboxy prothrombin before hepatocellular carcinoma treatment can be associated with long-term liver dysfunction after treatment.

Masaya Saito1, Yasushi Seo, Yoshihiko Yano, Akira Miki, Masaru Yoshida, Takeshi Azuma.   

Abstract

BACKGROUND: Transcatheter arterial chemoembolization (TACE) is an effective treatment for hepatocellular carcinoma (HCC), but it sometimes makes liver function worse. The pre-TACE prediction of liver dysfunction after TACE would be helpful to avoid long-term liver dysfunction.
METHODS: We performed a case-control study in 100 HCC patients who underwent TACE at Kobe University Hospital. Urinary/blood biochemical examinations were performed before TACE. As an indicator of liver function, Child's score was also evaluated before and 3 months after TACE. Cases with and without an increase of 2 points or more in the Child's score were compared, and independent risk factors were statistically examined. A pre-TACE predictive model of an increase of 2 points or more in the Child's score after TACE was developed using logistic regression.
RESULTS: Univariate analyses showed that des-γ-carboxy prothrombin (DCP) and lactate dehydrogenase (LDH) before TACE were significantly higher in the Child's score-deteriorated group than in the group with no deterioration (p = 0.036 and 0.003, respectively). All possible multivariate regressions showed that DCP (p = 0.003) and LDH (p = 0.002) were independent factors determining the deterioration of Child's class. A predictive model was developed, as follows: exp(0.014 × LDH + 0.572 × ln(DCP) - 8.655)/(1 + exp(0.014 × LDH + 0.572 × ln(DCP) - 8.655)). The model discriminated well, with AUC being 0.837 (95 % confidence interval [CI] 0.662-1.000). The optimal cut-off point was 0.073, and the sensitivity and specificity were 90.9 and 69.7 %, respectively.
CONCLUSIONS: High values of DCP and LDH before TACE were associated with the long-term deterioration of liver function. Our pre-therapeutic prediction model could be useful to identify high-risk cases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22441533     DOI: 10.1007/s00535-012-0577-0

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  35 in total

1.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

2.  Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.

Authors:  S D Ryder
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

3.  Transcatheter arterial embolization in unresectable hepatocellular carcinoma.

Authors:  R Yamada; K Kishi; T Sonomura; M Tsuda; S Nomura; M Satoh
Journal:  Cardiovasc Intervent Radiol       Date:  1990 Jun-Jul       Impact factor: 2.740

4.  Hepatic artery flow and propranolol metabolism in perfused cirrhotic rat liver.

Authors:  D G Le Couteur; H Hickey; P J Harvey; J Gready; A J McLean
Journal:  J Pharmacol Exp Ther       Date:  1999-06       Impact factor: 4.030

5.  BCAA-enriched snack improves nutritional state of cirrhosis.

Authors:  Yutaka Nakaya; Kiwamu Okita; Kazuyuki Suzuki; Hisataka Moriwaki; Akinobu Kato; Yoshiyuki Miwa; Koichi Shiraishi; Hiroaki Okuda; Morikazu Onji; Hidenori Kanazawa; Hirohito Tsubouchi; Shinzo Kato; Masahiko Kaito; Akiharu Watanabe; Daiki Habu; Susumu Ito; Tomohisa Ishikawa; Naohiro Kawamura; Yasuyuki Arakawa
Journal:  Nutrition       Date:  2007-02       Impact factor: 4.008

6.  Short-term reductions in non-protein respiratory quotient and prealbumin can be associated with the long-term deterioration of liver function after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.

Authors:  Masaya Saito; Yasushi Seo; Yoshihiko Yano; Akira Miki; Masaru Yoshida; Takeshi Azuma
Journal:  J Gastroenterol       Date:  2012-02-18       Impact factor: 7.527

7.  Hypoxia-induced des-gamma-carboxy prothrombin production in hepatocellular carcinoma.

Authors:  Kazumoto Murata; Hideto Suzuki; Hiroshi Okano; Takashi Oyamada; Yoshikazu Yasuda; Atsushi Sakamoto
Journal:  Int J Oncol       Date:  2010-01       Impact factor: 5.650

8.  Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC.

Authors:  G Pelletier; M Ducreux; F Gay; M Luboinski; H Hagège; T Dao; W Van Steenbergen; C Buffet; P Rougier; M Adler; J P Pignon; A Roche
Journal:  J Hepatol       Date:  1998-07       Impact factor: 25.083

9.  Reduced liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice.

Authors:  Jeon-Ok Moon; Timothy P Welch; Frank J Gonzalez; Bryan L Copple
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-01-08       Impact factor: 4.052

10.  Application of multiple statistical tests to enhance mass spectrometry-based biomarker discovery.

Authors:  Niclas C Tan; Wayne G Fisher; Kevin P Rosenblatt; Harold R Garner
Journal:  BMC Bioinformatics       Date:  2009-05-14       Impact factor: 3.169

View more
  3 in total

Review 1.  Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma.

Authors:  Hao Xing; Cunling Yan; Liming Cheng; Nianyue Wang; Shuyang Dai; Jianyong Yuan; Wenfeng Lu; Zhouchong Wang; Jun Han; Yijie Zheng; Tian Yang
Journal:  Tumour Biol       Date:  2016-10-13

2.  Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy.

Authors:  Kei Moriya; Tadashi Namisaki; Hiroaki Takaya; Kosuke Kaji; Hideto Kawaratani; Naotaka Shimozato; Yasuhiko Sawada; Akitoshi Douhara; Shinya Sato; Masanori Furukawa; Koh Kitagawa; Takemi Akahane; Hitoshi Yoshiji
Journal:  J Clin Med       Date:  2021-02-07       Impact factor: 4.241

3.  Alteration of non-protein respiratory quotient after hepatocellular carcinoma treatment can be related to des-γ-carboxy prothrombin before treatment.

Authors:  Masaya Saito; Yasushi Seo; Yoshihiko Yano; Akira Miki; Kenji Momose; Hirotaka Hirano; Masaru Yoshida; Takeshi Azuma
Journal:  Springerplus       Date:  2012-11-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.